2020-07-09 Authoring Group Meeting Agenda and Notes

Attendees

 

Attended

Name

Affiliation

 

Attended

Name

Affiliation

1

 

@Cary Paul

Pivotal Insight, LLC.

2

x

David Crooke

Pivotal Insight, LLC.

3

 

Amy Stowers

Maximus

4

x

Ken Rubin

VA/Utah

5

x

Linda Chan

Pivotal Insight, LLC.

6

x

Dhruv Sharma

ACEP

7

x

John Svirbely

Trisotech

8

x

Shane McNamee

Perspecta

9

 

Tracie Berardi

OMG

10

x

Pawan Goyal

ACEP

11

x

Mike Cesino

 Visible Systems Corporation

12

x

Mike Meier

 

Agenda and Minutes


Agenda Item

Agenda Item

Meeting Notes

 

Meeting Notes

 

Business Use Case Analysis

  • Who are the buyers

  • What is the price

  • Business Trends

  • ROI

  • Spans the communities and holistic around all of BPM+

Statement of Value

  • What is the benefits

  • What are the key value statements for different action and communications

  • Target Audience: Arriving toward and organization that wants to do authoring of clinical pathways

  • Differentiate between those that want to do authoring verse those that are trying to consume authored artifacts

Out of Scope of Authoring Work group

  • Why an institution would want to adopt or institute shareable pathways

  • Bill: Are there studies about how pathways are instituted and used, and the implications of that. (ref: Look at oncology Pathways)

Examples:

Clinical Pathways: Reducing Costs and Improving Quality Across a Network

Impact of Electronically Accessible Pathways on Clinical Trial Enrollment at a Large Multisite Cancer Center

Work What Success looks like? (6-12 mos)

  • Why would someone want to be involved

  • What is the path-How do I start, and what does the path look like?

  • Best practices-how do I do this well ? What has been learned? What guidance should I follow?

  • Why should I want to be an author involved in BPM+?

  • “How does one take a 100+page PDF guideline and make it into a machine readable model that could be ingested into a system.” Taking the story, approach, tips, tricks, etc. so that other can do this. Either de novo or adapting existing content. This is authoring.

    • New clinical societies

    • Healthcare delivery orgs

    • Etc.

  • Why would an organization choose this ?

  • If we make the decision, how do we make it so?

  • What does “doing it well” looks like: (e.g. Maturity Model, etc.)

Sample: The Product Vision Board

Work Products to do this

  • Artifact: Criteria Set/Guide ( ?)

    • Purpose: Define what a well authored model looks like

    • Audience: Person or org stepping up and establishing an authoring capability

      • As a Technologies: Defines what a well authored model looks like

      • As a Functional: Shows what a well authored model looks like

      • Business: secondary reference

    • Contents:

      • Investments that would need to be made (e.g Tooling, training

      • How to address variability and drive towards consistency (e.g., glossaries, patterns, standardized nomenclature, terminology) ; recognize and applying patterns

      • Snapshot of good authoring practices, approaches. Best practices, characteristics, etc. Potential maturity model to advance organizational capacity to develop pathways.

      • Quality criteria-what represents a good authored artifacts.

      • Dealing with settings, variances, local adaptation/configuration

      • Access to functional expertise

Work Products to do this

What is the artifact: Value Proposition for Authoring Organizations

  • What is the purpose

    • Explain why formal authoring is valuable

    • Helping advance usability of EHRs: role in improving efficacy of EHR

    • Marrying CPGs into clinical practice congruent to clinical workflow;

    • Making these more consumable and implementable

  • Who is its audience:

    • As a Technologies: Clinical embeds supporting technology companies

    • As a Functional: Full spectrum clinical community, those building guidelines or maintaining them;

    • Business: secondary reference

    • Adopting organization: rationalize the art of the possible; value of direct consumption of guidelines.

    • Specialty Societies: Authoritative creators or stewards of content.

    • Payers:

  • Contents:

    • Mission

    • Specific Purpose

    • “Customers”

    • Problem being solved

    • Unique value proposition

    • Case Studies/Exemplars

Action items:

  • Review and integrate business case outline with the new artifacts

  • Linda Chan to set up 2 sub meetings

    • Value Prop-Shane McNamee, Mike Cesino, Pawan Goyal

    • Criteria-Mike Meir/John Svirbely

Next Mtgs:

  • Workgroup on Monday, July 20 2:30pm – 4pm EST

  • Authoring Clinical Steering Committee on Thursday, July 23, 12:00PM – 1:00pm EST

  • Workgroup on Monday, August 3 2:30pm – 4pm EST

  • Authoring Clinical Steering Committee on Thursday, Aug 23, 12:00PM – 1:00pm EST